|
Name |
Epoxyjanthitrem I
|
Molecular Formula | C39H51NO7 | |
IUPAC Name* |
[13-hydroxy-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,11,24-trioxa-32-azanonacyclo[16.14.0.02,16.03,13.06,12.010,12.019,31.021,29.022,27]dotriaconta-1(18),19,21(29),26,30-pentaen-9-yl]acetate
|
|
SMILES |
CC(=O)OC1C(C(C)(C)O)OC2CCC3(C)C4(C)c5[nH]c6cc7c(cc6c5CC4CCC3(O)C23OC13)CC1C7=CC(C)(C)OC1(C)C
|
|
InChI |
InChI=1S/C39H51NO7/c1-19(41)44-29-31(34(4,5)42)45-28-11-12-36(8)37(9)21(10-13-38(36,43)39(28)32(29)46-39)16-24-23-14-20-15-26-25(18-33(2,3)47-35(26,6)7)22(20)17-27(23)40-30(24)37/h14,17-18,21,26,28-29,31-32,40,42-43H,10-13,15-16H2,1-9H3/t21?,26?,28?,29-,31+,32-,36-,37-,38+,39+/m1/s1
|
|
InChIKey |
PIUNYKDDCZGGMI-IZKGHWMTSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 645.84 | ALogp: | 5.7 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 113.5 | Aromatic Rings: | 9 |
Heavy Atoms: | 47 | QED Weighted: | 0.279 |
Caco-2 Permeability: | -5.074 | MDCK Permeability: | 0.00001510 |
Pgp-inhibitor: | 1 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.306 | 20% Bioavailability (F20%): | 0.097 |
30% Bioavailability (F30%): | 0.852 |
Blood-Brain-Barrier Penetration (BBB): | 0.743 | Plasma Protein Binding (PPB): | 95.29% |
Volume Distribution (VD): | 1.982 | Fu: | 4.68% |
CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.59 |
CYP2C19-inhibitor: | 0.045 | CYP2C19-substrate: | 0.698 |
CYP2C9-inhibitor: | 0.32 | CYP2C9-substrate: | 0.073 |
CYP2D6-inhibitor: | 0.122 | CYP2D6-substrate: | 0.594 |
CYP3A4-inhibitor: | 0.503 | CYP3A4-substrate: | 0.875 |
Clearance (CL): | 5.762 | Half-life (T1/2): | 0.01 |
hERG Blockers: | 0.745 | Human Hepatotoxicity (H-HT): | 0.401 |
Drug-inuced Liver Injury (DILI): | 0.035 | AMES Toxicity: | 0.023 |
Rat Oral Acute Toxicity: | 0.982 | Maximum Recommended Daily Dose: | 0.938 |
Skin Sensitization: | 0.017 | Carcinogencity: | 0.815 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.986 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001966 | 0.514 | D0H2MO | 0.231 | ||||
ENC003931 | 0.491 | D0OT9S | 0.226 | ||||
ENC003930 | 0.491 | D0V6OA | 0.221 | ||||
ENC003787 | 0.478 | D0W9MM | 0.220 | ||||
ENC002013 | 0.475 | D0X7XG | 0.219 | ||||
ENC003929 | 0.469 | D0W2EK | 0.219 | ||||
ENC002359 | 0.434 | D01HTL | 0.214 | ||||
ENC003875 | 0.429 | D02JNM | 0.213 | ||||
ENC003834 | 0.404 | D09QVV | 0.212 | ||||
ENC001508 | 0.402 | D03ZZK | 0.212 |